Competition in the ever-growing market for obesity treatments continues to mount, with positive early data for Hong Kong’s ...

Ascletis Pharma has reported positive topline outcomes from its US Phase Ia single ascending dose (SAD) study of the oral ...

Ascletis announces positive results from US phase Ia SAD study of small molecule oral GLP-1R agonist ASC30 in patients with obesity: Hong Kong, China Wednesday, January 22, 2025, ...

Doctors worldwide should diagnose obesity differently, relying on broader criteria and taking into account when the condition ...

Eli Lilly's popular obesity drug Zepbound can now be covered by government-backed Medicare drug plans, CNBC reported on Wednesday, citing the Centers for Medicare & Medicaid Services.

Compared with poor response, good response to obesity treatment was associated with lower risk of type 2 diabetes (adjusted ...

Clinical obesity -- now defined as a state of ongoing illness -- is hallmarked by reduced tissue or organ function due to ...

Scheduled for 13 weeks, the trial will assess the therapy’s safety, tolerability, and efficacy in weight loss.

Data from a Phase Ia single ascending dose study found that ASC30 demonstrated dose-proportional pharmacokinetics, a ...

The trial will enrol nearly 280 adult subjects with obesity. Credit: Hunterframe / Shutterstock. Viking Therapeutics has announced the start of a Phase II clinical trial for VK2735, an oral tablet ...

Shares of Novo Nordisk and Eli Lilly gain following study results that show GLP-1 drugs cut the risk of heart and kidney ...

13-Week Study to Evaluate the Safety and Efficacy of Oral VK2735 Dosed Once Daily SAN DIEGO, Jan. 8, 2025 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage ...